Medicines: permissions and operating records · France / Switzerland
Clinical trial sponsor: prepare the submission dossier
A sponsor’s clinical-trial dossier links the study, investigational product, sites and delegated duties to the required submissions and decisions. France’s European clinical-trial route and Switzerland’s authority and ethics framework must be assessed separately. Keep protocol versions, participant materials, changes and follow-up traceable. Preparation organises regulatory evidence; it does not approve the science, assess an individual’s treatment or replace participant-facing consent advice.
Julie by AlphaDeep is an AI legal assistant for French law: it researches official references to help answer your questions (Légifrance, case law, service-public), analyses your documents and drafts your letters, for individuals and professionals alike.
- Jurisdiction
- Study and sponsor
- Protocol and version
- Submissions and decisions
- Sites and changes
- Official texts cited
- Sources checked on
- Drafted with AI assistance, our method
General legal information with official references and dated checks. It is not personalised advice: for a decision that commits you, have your situation checked by a qualified professional.
Julie by AlphaDeep
Which regulatory framework matches the product and trial?
France: establish whether the study falls within the medicines-trial framework referenced by ANSM. Switzerland: justify the KlinV category from product and use; French or EU classification does not establish the Swiss category automatically.
Read the referencesYour file concerns “Clinical trial sponsor: prepare the submission dossier”. Does it concern France or Switzerland? Share the document for study and sponsor and the decision you need to prepare.
3 free questions at signup. Avoid names and sensitive information.
Which study and sponsor define the dossier?
France: identify trial, medicine, sponsor, sites and participating countries. Switzerland: additionally document the sponsor’s Swiss seat or representation under KlinV Article 2; a protocol title alone does not assign the project’s responsibilities.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Protocol, submission and sponsor-responsibility matrix
Synthetic example: fictional records. Protocol, submission and sponsor-responsibility matrix.
Synthetic example: fictional records · Protocol, submission and sponsor-responsibility matrix
- Jurisdiction
- France
- Study and sponsor
- Trial E1, sponsor S1
- Protocol and version
- Version P1, date D1
- Submissions and decisions
- Dossier A1, opinion C1
- Sites and changes
- Sites T1, amendment M1
Preparation organises regulatory evidence; it does not approve the science, assess an individual’s treatment or replace participant-facing consent advice.
Which regulatory framework matches the product and trial?
France: establish whether the study falls within the medicines-trial framework referenced by ANSM. Switzerland: justify the KlinV category from product and use; French or EU classification does not establish the Swiss category automatically.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Preparation reference: Protocol, submission and sponsor-responsibility matrix
| Preparation question | Point to verify |
|---|---|
| Which study and sponsor define the dossier? | France: identify trial, medicine, sponsor, sites and participating countries. Switzerland: additionally document the sponsor’s Swiss seat or representation under KlinV Article 2; a protocol title alone does not assign the project’s responsibilities. |
| Which regulatory framework matches the product and trial? | France: establish whether the study falls within the medicines-trial framework referenced by ANSM. Switzerland: justify the KlinV category from product and use; French or EU classification does not establish the Swiss category automatically. |
| What protocol and supporting-document versions must agree? | France: link protocol, participant information and consent versions by language and site. Switzerland: maintain the same document traceability for the Swiss submissions; a later draft must not silently replace the version previously reviewed. |
| Which authority and ethics submissions or decisions are required? | France: the Commission identifies CTIS as the submission entry point for the Regulation’s trials. Switzerland: distinguish ethics approval and any required Swissmedic decision; neither a portal receipt nor an exemption note proves all approvals exist. |
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
What protocol and supporting-document versions must agree?
France: link protocol, participant information and consent versions by language and site. Switzerland: maintain the same document traceability for the Swiss submissions; a later draft must not silently replace the version previously reviewed.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which authority and ethics submissions or decisions are required?
France: the Commission identifies CTIS as the submission entry point for the Regulation’s trials. Switzerland: distinguish ethics approval and any required Swissmedic decision; neither a portal receipt nor an exemption note proves all approvals exist.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which official provision helps explain this situation?
A sponsor’s clinical-trial dossier links the study, investigational product, sites and delegated duties to the required submissions and decisions. France’s European clinical-trial route and Switzerland’s authority and ethics framework must be assessed separately. Keep protocol versions, participant materials, changes and follow-up traceable. Preparation organises regulatory evidence; it does not approve the science, assess an individual’s treatment or replace participant-facing consent advice.
What duties are allocated to sites and service providers?
France: map sponsor, site and contractor tasks to the actual agreements. Switzerland: distinguish sponsor and investigator responsibilities under KlinV Article 2; record missing assignments without treating delegation as proof that all oversight duties are discharged.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
How are participant information and consent documented?
France: retain the information and consent package matching the reviewed protocol. Switzerland: connect these documents to the relevant ethics record and language; this general preparation tool should not contain identifiable participant health records.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which amendments, notifications and follow-up records are required?
France: track proposed amendments, safety events, submissions and decisions separately, checking the applicable rules. Switzerland: identify the relevant KlinV change or reporting branch; this chronology supplies no universal deadline or automatic amendment approval.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Why is sponsor preparation distinct from individual participant advice?
France: this output supports the sponsor’s regulatory preparation rather than individual treatment choices. Switzerland: a category A exemption from Swissmedic authorisation does not remove the ethics-review requirement; document the two questions separately.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which preparation steps come first?
Editorial preparation order, not a popularity or success-probability ranking. Order preparation by dependency: trial classification, coherent protocol, required decisions, then implementation and follow-up.
Define the trial
Product, sponsor and countries determine the evidence to assemble before filing.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Justify classification
The governing study category controls the permission questions; labels alone cannot settle it.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Align document versions
Protocol and participant-document mismatches prevent reliable comparison with reviewed submissions.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Connect decisions
Separate submission receipts from the actual decisions and any specifically justified exemptions.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Assign follow-up
Name the person responsible for each unresolved task, change and reporting action.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which official references should you consult?
- Commission européenne : essais cliniques et CTIShealth.ec.europa.eu
- ANSM essai cliniqueansm.sante.fr
- OClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34www.fedlex.admin.ch
- LRH / HFG / LRUm : 45, 19, 20www.fedlex.admin.ch
- Swissmedic clinical-trial applicationswww.swissmedic.ch
Texts cited last checked: 3 November 2026
What other questions arise in this file?
Which regulatory framework matches the product and trial?
France: establish whether the study falls within the medicines-trial framework referenced by ANSM. Switzerland: justify the KlinV category from product and use; French or EU classification does not establish the Swiss category automatically.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Which authority and ethics submissions or decisions are required?
France: the Commission identifies CTIS as the submission entry point for the Regulation’s trials. Switzerland: distinguish ethics approval and any required Swissmedic decision; neither a portal receipt nor an exemption note proves all approvals exist.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
How are participant information and consent documented?
France: retain the information and consent package matching the reviewed protocol. Switzerland: connect these documents to the relevant ethics record and language; this general preparation tool should not contain identifiable participant health records.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications
Why is sponsor preparation distinct from individual participant advice?
France: this output supports the sponsor’s regulatory preparation rather than individual treatment choices. Switzerland: a category A exemption from Swissmedic authorisation does not remove the ethics-review requirement; document the two questions separately.
Commission européenne : essais cliniques et CTISANSM essai cliniqueOClin / KlinV / OSRUm : 2, 19, 23, 24, 25, 30, 31, 34LRH / HFG / LRUm : 45, 19, 20Swissmedic clinical-trial applications